Good afternoon :)
$
₹
E

ELECTRA+THERAPEUTICS+INC

ETRA

US
E

ELECTRA+THERAPEUTICS+INC

ETRA

US
$9.221.92% (+0.17)
$
₹
$9.221.92% (+0.17)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $553.0M the stock is ranked 3214

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.65
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 4 analysts reports

Buy
4 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+260.36%

Earnings Growth

—

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$9.25Baseline
Analyst Target - 1 year
Target$33.33+260.36%

All values in $

20232024202520262027$15.41$22.49$29.58Target+260.36%
2026
Current$9.25Baseline
Analyst Target - 1 year
Target$33.33+260.36%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

Q4 2025
Q2 2026
Revenue
Net Income
Financial YearQ4 2025Q2 2026
Total Revenue--
Net Income--
Net Profit Margin--
See CostsAll values in $ Billion

Peers

Price Comparison

Compare ETRA with any stocks or ETF

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Frequently asked questions

  1. ELECTRA+THERAPEUTICS+INC (ETRA) share price today is $9.22 as of October 23, 2026 at 1:30 AM IST. The stock touched a day high of $9.58 and a day low of $9.00.

  2. ELECTRA+THERAPEUTICS+INC stock trades on US under the ticker symbol ETRA.

  3. ELECTRA+THERAPEUTICS+INC's market capitalization is $552.97M as of October 23, 2026 at 1:30 AM IST.

  4. ELECTRA+THERAPEUTICS+INC's price-to-earnings (P/E) ratio is N/A as of October 22, 2026.

  5. ELECTRA+THERAPEUTICS+INC's price-to-book (P/B) ratio is 0 as of October 22, 2026.

  6. Yes, You can buy ELECTRA+THERAPEUTICS+INC shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy ELECTRA+THERAPEUTICS+INC shares in three steps: 1. Search ELECTRA+THERAPEUTICS+INC on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since ELECTRA+THERAPEUTICS+INC trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in ELECTRA+THERAPEUTICS+INC (ETRA) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.0841 shares at the current price of $9.22.

Loading...